Security Asset Management reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 12.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,967 shares of the company’s stock after selling 3,004 shares during the quarter. Johnson & Johnson accounts for 2.2% of Security Asset Management’s holdings, making the stock its 16th largest position. Security Asset Management’s holdings in Johnson & Johnson were worth $3,588,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its position in Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares in the last quarter. FMR LLC increased its holdings in Johnson & Johnson by 20.8% in the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares in the last quarter. GQG Partners LLC raised its position in Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of Johnson & Johnson by 52.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock valued at $1,083,329,000 after purchasing an additional 2,093,392 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares in the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several research firms have commented on JNJ. Bank of America cut their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research note on Friday, October 14th. SVB Leerink lowered their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Citigroup upped their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Raymond James dropped their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Finally, Barclays assumed coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $181.75.
Insider Buying and Selling
Johnson & Johnson Stock Performance
NYSE JNJ opened at $168.31 on Wednesday. The business’s 50-day moving average price is $175.98 and its 200 day moving average price is $171.06. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The firm has a market cap of $440.04 billion, a P/E ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.23 by $0.12. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same quarter in the previous year, the company posted $2.13 earnings per share. The company’s revenue for the quarter was down 4.4% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio is currently 62.95%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.